

SC • IV
Pr Aranesp[®]
(darbepoetin alfa)

>500,000 PATIENTS 
TREATED WITH ARANESP

>11 MILLION DOSES* 
DISTRIBUTED TO DATE¹

WE'RE CELEBRATING 20 YEARS IN CANADA
Amgen is honoured to have worked with the
nephrology healthcare community since 2002



Aranesp[®] (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.²

Please consult the Product Monograph at http://www.amgen.ca/Aranesp_PM.pdf for contraindications, warnings, precautions, adverse reactions, interactions, conditions of clinical use, and dosing (particularly regarding the administration of Aranesp[®] under the supervision of a healthcare professional, the longer serum half-life of Aranesp[®] compared to epoetin alfa, and the dosing and monitoring information when changing the route of administration) which have not been discussed in this piece.

The Product Monograph is also available by calling Amgen Canada Medical Information at: 1-866-502-6436.

*1 pre-filled syringe=1 dose.

SC • IV
Pr **Aranesp**[®]
(darbepoetin alfa)



TOGETHER, WE'VE COME A LONG WAY IN 20 YEARS!

We would like to express our sincere thanks to nephrology healthcare professionals like you for the work you do to care for patients with chronic kidney disease.

**BUILDING UPON AMGEN'S NEPHROLOGY
HERITAGE WITH ONGOING INVESTMENT
TO SUPPORT PATIENTS AND
THOSE INVOLVED IN THEIR CARE**

Giving back to the nephrology community by supporting:



National nephrology
associations

National and regional
educational events for
nephrology healthcare
professionals

Education and tools for
nephrology healthcare
professionals

Patient education tools

Patient-oriented research

References: 1. Amgen Canada Inc., Data on File. 2. Aranesp[®] (darbepoetin alfa) Product Monograph. Amgen Canada Inc. May 24, 2018.

© 2022 Amgen Canada Inc. All rights reserved.

Aranesp[®] is a registered trademark of Amgen Inc., used with permission by Amgen Canada Inc.

ARA192E-22

